Biosciences

Ìý

A interdisciplinary life science innovation ecosystem built to solve industry R&D challenges

To accelerate the path from discovery to patient impact, ÂÌñ»»ÆÞ integrates:

  • ÌýÌýBiology

  • ÌýÌýEngineering

  • ÌýÌýChemistry

  • ÌýÌýPhysics

  • ÌýÌýComputational platforms

  • ÌýÌýClinical collaboration

Strategic Focus Areas

Drug Discovery Tools & Enabling Technologies
Tissue Engineering, Regenerative Medicine & Translational Models
AI, Computational Models & Digital Twins
Medical Devices, Imaging & Surgical Technologies

Primary Therapeutic Areas


ÌýÌýOncology


ÌýÌýCardiovascular


ÌýÌýNeuroscience


ÌýÌýMetabolic Disease

ÌýÌýImmunology

ÌýÌýInfectious Disease

ÌýÌýRare Disease

ÌýÌýRegenerative Medicine

Resources & Infrastructure

Core Facilities and Shared Instrumentation

  • Advanced Microscopy & Imaging
  • Flow Cytometry & Cell Analysis
  • DNA/RNA Sequencing
  • Mass Spectrometry
  • High-Throughput Screening
  • Microfabrication
  • Bioinformatics & High-Performance Computing
COSINC

BioFrontiers Institute

An interdisciplinary bioscience institute accelerating translational discovery and industry collaboration by integrating:

  • Biology
  • Chemistry
  • Physics
  • Engineering
  • Predictive modelingÌý
BioFrontiers Institute

Anschutz-Boulder (AB) Nexus

Bridging discovery and clinical insight through collaborations between ÂÌñ»»ÆÞ and the CU Anschutz Medical Campus:

  • Seed-funded partnerships
  • Integrates ÂÌñ»»ÆÞ research with clinicians
  • Enables clinical validation
    Ìý
Researchers working on an AB Nexus collaboration

Thriving Startup Ecosystem

ÂÌñ»»ÆÞ ranked #1 among U.S. universities for startups creation in 2024.Ìý

Our spinouts are shaping modern biotechnology and translational innovation, including:

Ìý

Think Bioscience

Synthetic biology platform targeting undruggable proteins; $55M Series A

Ìý

MyoKardia

Developed small-molecule cardiac myosin modulators for hypertrophic cardiomyopathy and heart failure; acquired by Bristol Myers Squibb for $13.1B

Capabilities & Applications

Target Discovery, Mechanism-of-Action & Pathway Biology Medical Devices, Robotics & Digital Twin Systems Engineered Disease & Tissue Modeling Platforms Optimizing RNA Therapeutics & Programmable Gene Control
Target Discovery, Mechanism-of-Action & Pathway Biology

Core Challenge

Biopharma: Therapeutic programs struggle to translate complex disease biology into predictable clinical performance, leading to inconsistent efficacy and limited durability across patient populations.

CU Capabilities

Multiomics, pathway biology, and structure-based modeling used to validate target engagement, define mechanisms of action and identify resistance drivers—enabling the design of more effective therapeutics.

Core Challenge

Medtech: Interventional procedures and medical device development face variability in precision, limited real-time sensing, and incomplete understanding of device–tissue interaction, constraining procedural consistency, safety and long-term performance.

CU Capabilities

Intelligent medical devices, image-guided surgical robotics, embedded sensing platforms, and computational digital twins that model device–tissue interaction, biomechanics, and flow dynamics, improving navigation precision, real-time feedback and device performance validation.

Core Challenge

Biotech & MedTech Industry: Preclinical models often fail to replicate human tissue biology and microenvironmental complexity, limiting translational predictability, therapeutic screening accuracy and regenerative performance.

CU Capabilities

Tissue & Disease Models: Tunable biomaterials, engineered microenvironments, organoid systems, and tissue models that recreate human-relevant biology to improve therapeutic evaluation, disease modeling, and regenerative medicine development.

Core Challenge

Biopharma: RNA-based therapies face instability, unintended immune activation, and inconsistent translational efficiency, limiting durability and clinical performance.

CU Capabilities

We engineer RNA stability and programmable translational control systems to enhance therapeutic durability, modulate immune activation, and improve precision in RNA and gene-targeted therapeutics.

Industry Impact

  • Tom Cech: Nobel Laureate; discovered catalytic RNA, foundational to RNA therapeutics
  • Marvin Caruthers: Co-founder of Amgen, inventor of phosphoramidite DNA synthesis
  • Leslie Leinwand: Leader in cardiac and muscle biology; ~$15B+ in cardiomyopathy-related exits
  • Larry Gold: Founder, SomaLogic acquired by Illumina (2024, ~$425M); pioneer of large-scale proteomics and precision biomarker discovery
    Ìý

Partnering with the Biosciences Ecosystem

We simplify the path to innovation for our corporate and government partners:

Ìý

Streamlined contracting pathways

Guided by tools to reduce negotiation timelines (e.g. term sheets and modular IP menus)

Ìý

Industry Research Partnerships (IRP)

Dedicated team providing concierge-level support for research collaborationsÌý

Ìý

Talent recruitment, shared facilities and testing services

Access to faculty expertise, unique instrumentation and emerging talent pipelinesÌý

Ìý

Venture Partners at ÂÌñ»»ÆÞ

Campus commercialization arm that spins out startups

Connect with Us

Chris Gustavson

Executive Director, Industry Research Partnerships
RESEARCH & INNOVATION OFFICE
ÌýÌýchris.gustavson@colorado.edu

Ari Marcellino

Associate Director, Biosciences
INDUSTRY RESEARCH PARTNERSHIPS
ÌýÌýari.marcellino@colorado.eduÌý